Peter Bains to replace Jonathan Hunt as CEO of Syngene

Peter Bains has over three decades of experience in the biotech and pharmaceutical industry

Cosmo and Glenmark receives UK MHRA approval to market Winlevi in UK

Merck reports 2024 sales at $64.2 billion

The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis

Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo

Hikal Q3 FY25 consolidated revenue recorded at Rs. 448 Cr

The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile

Philogen completes patient enrollment of Phase III FIBROSARC trial in Soft Tissue Sarcoma

These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential

JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%

Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24

Pfizer reports 2024 revenues 7% higher at $63.6 billion

Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion

Pharmexcil appoints Bhavin Mukund Mehta as Vice Chairman

Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment diabetes-related blindness

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)